Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VENLID: 10%-Lidocaine Spray Prior to PIVC Insertion
NCT06354816Phase 4Completed
- Start
- May 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of lidocaine 10% oropharyngeal spray in pain (4 arms). Primary endpoint: Pain Difference Caused by PIVC Rated by NRS Between Application of 10% Lidocaine Spray and Placebo at 2 minutes. Started May 2024; status: completed.
02
Drugs
lidocaine 10% oropharyngeal spray
03
Conditions
pain
Beyond the preview
Go deeper on NCT06354816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06354816.